ANP Technologies®, Inc.

824 Interchange Boulevard  Newark, Delaware 19711

302-283-1730

info@anptinc.com

  • Black Facebook Icon
  • Black Twitter Icon
  • Black YouTube Icon

Copyright 2018

ANP Technologies®, Inc.

Immunogenicity

The exceptional growth of biotherapeutics to a $125 billion industry has brought the benefit of targeted therapy to patients. However, as more and more biotherapeutic "generics" are developed, the risk of unwanted immunogenicity grows. ANP has successfully collaborated with biopharmaceutical companies to create novel solutions for immunogenicity and create new possibilities for biotherapeutics breakthroughs. From our highly sensitive NIDS® Streptavidin & Neutravidin plates to our unrivaled NIDS® immunogenicity assays, ANP is providing the innovation for healthcare transformation.